Clene’s (CLNN) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Clene (NASDAQ:CLNN) in a report released on Thursday morning,Benzinga reports. The firm currently has a $23.00 target price on the stock.

A number of other equities analysts have also commented on the company. HC Wainwright reissued a “buy” rating and issued a $31.00 price objective on shares of Clene in a research note on Thursday, November 14th. Benchmark dropped their target price on shares of Clene from $90.00 to $84.00 and set a “buy” rating for the company in a research note on Friday, November 22nd. EF Hutton Acquisition Co. I raised shares of Clene to a “strong-buy” rating in a research note on Tuesday, September 10th. Finally, Canaccord Genuity Group reduced their price objective on Clene from $86.00 to $83.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $55.25.

Clene Stock Up 2.3 %

Shares of NASDAQ:CLNN opened at $4.40 on Thursday. The company has a market capitalization of $36.78 million, a PE ratio of -0.83 and a beta of 0.32. The company has a debt-to-equity ratio of 1.66, a quick ratio of 0.82 and a current ratio of 0.83. The company’s fifty day moving average is $4.98 and its 200-day moving average is $5.47. Clene has a 52 week low of $3.82 and a 52 week high of $11.00.

Insider Buying and Selling

In other Clene news, insider Mark Mortenson bought 20,512 shares of the stock in a transaction on Monday, September 30th. The stock was purchased at an average price of $4.75 per share, with a total value of $97,432.00. Following the acquisition, the insider now owns 28,949 shares of the company’s stock, valued at approximately $137,507.75. The trade was a 243.12 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David J. Matlin purchased 92,307 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was bought at an average cost of $4.75 per share, for a total transaction of $438,458.25. Following the purchase, the director now owns 444,491 shares in the company, valued at $2,111,332.25. This trade represents a 26.21 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 25.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Clene

A hedge fund recently bought a new stake in Clene stock. Castleview Partners LLC acquired a new position in shares of Clene Inc. (NASDAQ:CLNN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 12,783 shares of the company’s stock, valued at approximately $59,000. Castleview Partners LLC owned about 0.19% of Clene at the end of the most recent reporting period. Hedge funds and other institutional investors own 23.28% of the company’s stock.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.